Compounded
Semaglutide
Any prescribed dose up to 2.5 mg/week
Prescription & clinician review included
Shipping included
$948 due today
Also spelled as Cru Clinic, The Cru Clinic, cruclinic.com — Same brand, same great service!
Our investigation of Compounded Tirzepatide from Cru Clinic
Semaglutide programme from $249/month and tirzepatide from $349/month, each including medication and monthly nurse practitioner visits
These are Med Consumer Watch products, not products from Cru Clinic, the brand being reviewed on this page.
Med Consumer Watch GLP-1 plans
Med Consumer Watch exists to help consumers make informed choices. Our brand brings that mission to GLP-1 care: clear plan prices, clinician review and support included, so you can compare your options and get started with confidence.
Medication, clinician review and shipping are included. See your total before you buy.
Your plan price stays the same across its included prescribed doses. Choose 1, 3, 6 or 12 months.
Ongoing doctor messaging, health coaching and patient community access are included with your plan.
Choose your medication and the plan length that works for you.
Compounded
Any prescribed dose up to 2.5 mg/week
Prescription & clinician review included
Shipping included
$948 due today
Compounded
Any prescribed dose up to 15 mg/week
Prescription & clinician review included
Shipping included
$1,548 due today
Treatment requires a prescription and clinician approval. If treatment is declined, your payment is refunded. Compounded medications are not FDA-approved.
"COMPOUNDED SEMAGLUTIDE AND TIRZEPATIDE USED BY THE CRU CLINIC ARE NOT FDA-APPROVED BUT ARE PREPARED BY LICENSED U.S. COMPOUNDING PHARMACIES WHEN COMMERCIALLY AVAILABLE ALTERNATIVES ARE UNSUITABLE."That final clause is the actual legal standard. Since the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, a compounding pharmacy can no longer justify making copies of these drugs on shortage grounds. What remains lawful is patient-specific compounding where the commercially available product is genuinely unsuitable for that individual — a dose that is not manufactured, an excipient sensitivity, a specific titration requirement. Across everything we have reviewed, operators either ignore this entirely or say "not FDA-approved" and stop. Cru Clinic states the condition on which its compounding is lawful. That is the difference between disclosing a fact and disclosing a basis. It pairs this with the equally correct:
"ALL MEDICATIONS, INCLUDING SEMAGLUTIDE AND TIRZEPATIDE, REQUIRE A PRESCRIPTION FROM A LICENSED PROVIDER FOLLOWING A MEDICAL CONSULTATION."
"You must be a 30 BMI or higher to qualify for Phentermine."A specific, published numeric eligibility criterion. Most operators in this comparison publish none at all, and several set floors below the approved indication. BMI 30 is the correct threshold, and stating it lets a patient know before enquiring whether they qualify.
"The cost of the SEMAGLUTIDE program starts at $249 per month, which includes your medication and monthly visits/weigh-ins." · "The starting cost of the TIRZEPATIDE program is $349 per month, which includes your medication and monthly visits/weigh-ins for the starting dose."Both figures bundle medication with monthly in-person visits and weigh-ins with a Certified Nurse Practitioner. Note the honest qualifier on tirzepatide — "for the starting dose" — which signals that higher doses cost more rather than implying the price holds.
"We DO accept HSA plans, but we do not bill insurance for payment."
"These medications are not covered by most insurance plans, but manufacturer and pharmacy coupons can help offset the cost."Telling patients that manufacturer coupons exist — which apply to brand-name products Cru does not sell — is advice against its own commercial interest.
"The Cru Clinic is LegitScript-certified for safe telemedicine and prescription weight-management services."
Our research (September 2, 2026) found Cru Clinic publishing the most legally precise compounding disclosure of any consumer-facing operator in this comparison. Its statement that "compounded semaglutide and tirzepatide used by the Cru Clinic are not FDA-approved but are prepared by licensed U.S. compounding pharmacies when commercially available alternatives are unsuitable" articulates the actual post-shortage legal standard: following resolution of the tirzepatide shortage in October 2024 and semaglutide in early 2025, compounding these molecules can no longer be justified on shortage grounds, and what remains lawful is patient-specific compounding where the commercial product is genuinely unsuitable for that individual, such as an unmanufactured dose, an excipient sensitivity or a specific titration need. Operators elsewhere either omit this entirely or state only that products are not FDA-approved; Cru Clinic states the condition on which its compounding is lawful. It pairs this with a clear statement that all medications including semaglutide and tirzepatide require a prescription from a licensed provider following a medical consultation, and it publishes a specific numeric eligibility criterion — "you must be a 30 BMI or higher to qualify for Phentermine" — where most operators publish none and several set floors below the approved indication. Pricing bundles medication with care: the semaglutide programme starts at $249 per month and the tirzepatide programme at $349 per month, each including medication and monthly visits and weigh-ins with a Certified Nurse Practitioner, with the tirzepatide figure honestly qualified as applying "for the starting dose" rather than implying the price holds through titration. The clinic accepts HSA plans but does not bill insurance, and tells patients directly that these medications are not covered by most insurance plans while noting that manufacturer and pharmacy coupons can offset cost — advice pointing toward brand-name products it does not sell, and therefore against its own commercial interest. It is LegitScript-certified for telemedicine and prescription weight-management services. The disclosures are set in block capitals and contain typographical errors including "FRO A LICENSED" and "COMERCIALLY," which does not affect their substance but is careless in the sentence doing the most work. Not published: any named pharmacy or its 503A/503B status, a dose-tier schedule showing tirzepatide cost above the starting dose, a BMI criterion for the GLP-1s specifically as opposed to phentermine, laboratory requirements, titration protocols, founding year, state coverage, or refund terms.
Complete a medical consultation — required before any medication is prescribed
Check the published criterion: BMI 30 or higher is required to qualify for phentermine
Semaglutide programme starts at $249/month including medication and monthly visits
Tirzepatide programme starts at $349/month — note this is for the starting dose
Monthly visits and weigh-ins are with a Certified Nurse Practitioner
HSA plans are accepted; the clinic does not bill insurance
Ask what tirzepatide costs above the starting dose, since no tier schedule is published
Ask which pharmacy compounds your medication and under which pathway
Patients who want monthly in-person clinical review bundled with medication, from a clinic that states on what legal basis it compounds rather than leaving the question unasked
We assessed Cru Clinic against its published material as of September 2, 2026.
What we verified directly: semaglutide from $249/month and tirzepatide from $349/month, each including medication and monthly visits and weigh-ins with a Certified Nurse Practitioner; the tirzepatide figure qualified as applying to the starting dose; a published requirement of BMI 30 or higher to qualify for phentermine; LegitScript certification; HSA accepted but no insurance billing; and a compounding disclosure stating that preparations are used "when commercially available alternatives are unsuitable."
That last clause is the finding. It is the legal test that governs whether compounding these drugs is lawful now that the shortages have ended, and Cru Clinic is the only consumer-facing operator we have reviewed that states it. Most stop at "not FDA-approved," which discloses a fact without disclosing a basis.
Publishing a numeric BMI threshold is the second thing. BMI 30 for phentermine is the correct level, and stating any specific number puts Cru ahead of the many operators that publish no eligibility criteria at all.
Qualifying the tirzepatide price is a small honesty that matters. "$349 per month... for the starting dose" tells a patient the number will move. Competitors quote a starting figure and let the escalation arrive unannounced.
Mentioning manufacturer coupons is advice against interest. Those coupons apply to brand-name products Cru does not sell.
The presentation lets it down slightly. Block capitals and typos — "FRO A LICENSED," "COMERCIALLY" — in the very sentences that do the most work. The substance is right; the proofreading is not.
What we could not establish: the pharmacy and its pathway, tirzepatide pricing above the starting dose, GLP-1 eligibility criteria as distinct from phentermine, lab requirements, titration protocols, state coverage, refund terms, founding year, or independent third-party review aggregates.
"Is Cru Clinic legit?" Our assessment as of September 2, 2026.
Official Verification: Cru Clinic is LegitScript-certified for safe telemedicine and prescription weight-management services, requires a medical consultation before any prescription, and provides monthly in-person visits with a Certified Nurse Practitioner. We found no evidence of wrongdoing.
Understanding the rules is the strongest signal of a serious operator. "When commercially available alternatives are unsuitable" is not marketing language — it is the statutory condition, and reproducing it correctly means someone at the clinic read the framework rather than copying a competitor's disclaimer.
Publishing an eligibility number is the second. BMI 30 for phentermine is a real screen. Compare Healthy Living Clinic, whose BMI 25 floor sits below the approved indication with no comorbidity requirement.
Where to press. Cru states it compounds when commercial alternatives are unsuitable — so ask what makes them unsuitable in your case. That is the question its own disclosure invites, and a good clinic will have an answer. Also ask which pharmacy compounds your medication and what tirzepatide costs once you titrate past the starting dose.
On price, be realistic. $249 and $349 are above most compounded competitors. What you get for it is monthly in-person clinical review rather than asynchronous messaging, which is a real service, but it is worth comparing against Gentle Health or Cora Health on price alone.
Red Flags Check:
The Bottom Line: The only consumer-facing clinic we have reviewed that tells you the legal condition under which it compounds — which is exactly the question the rest of this category avoids. Ask what makes the commercial product unsuitable for you, and get the tirzepatide price at a maintenance dose before starting. As always, consult your personal physician before starting any new medication program.
Cru Clinic has a 8.5/10 site score. This provider has demonstrated excellent quality, transparent pricing, and reliable customer support. We recommend them for anyone considering GLP-1 treatment.
Visit Cru ClinicSemaglutide programme from $249/month and tirzepatide from $349/month, each including medication and monthly nurse practitioner visits
Help others by sharing your experience with Cru Clinic
Want to compare options?
View All 226 ProvidersNo ratings yet
Rate your experience
Click a star to rate and add a review
Compare with other GLP-1 weight loss providers we've investigated
Based on our investigation, Cru Clinic is a trusted choice for GLP-1 treatment. Join thousands who have started their weight loss journey.
Enter for a chance to use it toward eligible CoreAge Rx products and services.
The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.